摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-1,4-cyclopentandiol | 15786-48-8

中文名称
——
中文别名
——
英文名称
2-Methyl-1,4-cyclopentandiol
英文别名
4-Methylcyclopentane-1,3-diol
2-Methyl-1,4-cyclopentandiol化学式
CAS
15786-48-8
化学式
C6H12O2
mdl
——
分子量
116.16
InChiKey
DNVXWBJCNGBJOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    80 °C(Press: 0.05 Torr)
  • 密度:
    1.131±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:Aicher Thomas Daniel
    公开号:US20100204240A1
    公开(公告)日:2010-08-12
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    提供的化合物式(I)如下:其中R2、R3、R13、L和D2如规范中所定义,这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及本文所讨论的其他疾病和紊乱。
  • Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:AICHER Thomas Daniel
    公开号:US20120277242A1
    公开(公告)日:2012-11-01
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    本发明提供了式(I)的化合物:其中R2、R3、R13、L和D2如规范中所定义,它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用,或者可以通过激活葡萄糖激酶来治疗,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及其他疾病和疾病,如在此处所讨论的。
  • INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES
    申请人:Array BioPharma Inc.
    公开号:US20150057448A1
    公开(公告)日:2015-02-26
    Provided are intermediates having the formulas wherein R 2 , R 3 , and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.
    提供了中间体的公式,其中R2,R3和L的定义如规范中所述,这些中间体在制备吡啶-2-基氨基-1,2,4-噻二唑衍生物中很有用。
  • PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS
    申请人:Array Biopharma, Inc.
    公开号:EP3078662A1
    公开(公告)日:2016-10-12
    Provided are compounds of Formula I wherein R2, R3, R13 , L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    提供了式 I 的化合物 其中 R2、R3、R13、L 和 D2 如说明书中所定义,可用于治疗和/或预防由葡萄糖激酶活性水平不足介导或可通过激活葡萄糖激酶治疗的疾病或紊乱,包括但不限于糖尿病、糖耐量受损、空腹血糖受损和空腹血糖升高,以及其它疾病和紊乱,如本文所讨论的疾病和紊乱。
  • Method for preparing ethers of cycloaliphatic or araliphatic diols
    申请人:BASF SE
    公开号:US11078146B2
    公开(公告)日:2021-08-03
    The present invention relates to a method for preparing a dialkyi or dialkenyl ether of a cycloaliphatic or araliphatic diol, which comprises (i) reacting the cycloaliphatic or araliphatic diol with metallic sodium in an aprotic organic solvent in the presence of a catalytic amount of at least one monoether-monoalcohol of formula (I) wherein Y is identical or different and selected from C2-C4-alkylene, n is an integer in the range from 1 to 10, and R1 is C1-C4-Alkyl, whereby the corresponding disodium dialcoholate is obtained, reacting the disodium dialcoholate obtained in step (i) with an alkylation alkenylation reagent.
    本发明涉及一种制备环脂族或脂肪族二元醇的二酮基或二烯基醚的方法,其包括 (i) 在催化量的至少一种式(I)的单醚一元醇存在下,在非沸腾有机溶剂中使环脂族或脂肪族二元醇与金属钠反应,式(I)中Y为相同或不同且选自C2-C4-烯烃、n 为 1-10 之间的整数,R1 为 C1-C4 烷基,将步骤(i)中得到的二醇二钠与烷基化烯基化试剂反应,可得到相应的二醇二钠。
查看更多